It remains unclear how obesity worsens treatment outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). In normal pancreas, obesity promotes infl ammation and fi brosis. We found in mouse models of PDAC that obesity also promotes desmoplasia associated with accelerated tumor growth and impaired delivery/effi cacy of chemotherapeutics through reduced perfusion. Genetic and pharmacologic inhibition of angiotensin-II type-1 receptor reverses obesity-augmented desmoplasia and tumor growth and improves response to chemotherapy. Augmented activation of pancreatic stellate cells (PSC) in obesity is induced by tumor-associated neutrophils (TAN) recruited by adipocyte-secreted IL1β. PSCs further secrete IL1β, and inactivation of PSCs reduces IL1β expression and TAN recruitment. Furthermore, depletion of TANs, IL1β inhibition, or inactivation of PSCs prevents obesityaccelerated tumor growth. In patients with pancreatic cancer, we confi rmed that obesity is associated with increased desmoplasia and reduced response to chemotherapy. We conclude that cross-talk between adipocytes, TANs, and PSCs exacerbates desmoplasia and promotes tumor progression in obesity.
INTRODUCTION
Pancreatic cancer is the fourth-leading cause of cancerassociated death worldwide, with an overall 5-year survival rate of 7% ( 1 ). The risk of pancreatic cancer is about 50% greater for individuals with obesity, particularly those with increased abdominal adiposity ( 2 ) . Excess body weight also worsens the already dismal outcome of patients with pancreatic ductal adenocarcinoma (PDAC) by increasing the relative risk of cancer mortality by more than 2-fold (3) (4) (5) (6) (7) . As a consequence of the obesity pandemic-with nearly 70% of the U.S. adult population being either overweight or obese ( 8 )-the majority of patients with PDAC present with excess weight at diagnosis ( 6 ) . Thus, understanding why obesity is associated with a worse prognosis might lead to novel treatments and enhance the outcome of current therapies.
PDAC is a highly desmoplastic cancer characterized by activated pancreatic stellate cells (PSC) and an excessive accumulation of extracellular matrix (ECM; refs. 9, 10 ). ECM components and PSCs directly promote the survival and migration of cancer cells (11) (12) (13) . In addition, the interaction between cancer cells, stromal cells (e.g., PSCs), and the ECM produces physical forces (solid stresspressure from solid tissue components) which compress tumor blood vessels, thus causing poor and heterogeneous tumor perfusion ( 14, 15 ) . These mechanically induced changes in vascular perfusion create a formidable barrier to delivery and effi cacy of chemotherapeutics, leading to poorer treatment outcomes ( 11, (16) (17) (18) (19) . Importantly, obesity itself is a prodesmoplastic condition. The hypoxia that results from abnormal blood vessels and decreased blood fl ow due to the rapidly expanding white adipose tissue (WAT) in obesity causes adipocyte dysfunction and immune cell recruitment (20) (21) (22) . The latter leads to cytokine production, infl ammation, and ultimately fi brosis (20) (21) (22) . In particular, adipocytes in WAT abundantly express the angiotensin II type-1 receptor (AT1; refs. 23, 24 ), a major profi brotic pathway that becomes activated in a proinfl ammatory environment ( 23, 24 ) . Obesity also leads to fat accumulation in the normal RESEARCH ARTICLE pancreas (steatosis), which generates a similar infl ammatory process within the pancreas itself, with increased expression of cytokines, ECM remodeling, and fi brosis ( 7, 25, 26 ) . Importantly, cancer lesions in obese mice and patients have an increased adipocyte content ( 27, 28 ) . Of clinical relevance, the interaction of cancer cells with adipocytes-both in the form of accumulation of fat in the pancreas and at the invasive tumor front into the local adipose tissue-is associated with worse outcomes in patients with PDAC ( 7, 29 ) . However, the role of adipocytes during obesity-induced PDAC progression remains unclear.
We have previously reported that obesity promotes infl ammation (increased IL1β levels) and immune cell infi ltration in PDACs, which associates with increased tumor growth and metastasis ( 30 ) . Here, we hypothesized that the obesityassociated adipocyte accumulation in PDACs generates a proinfl ammatory and profi brotic microenvironment, which promotes tumor progression, and hinders the delivery and effi cacy of chemotherapy. In this study, we tested this hypothesis in patients with pancreatic cancer as well as in clinically relevant orthotopic and genetically engineered mouse models of PDAC. To reduce the obesity-instigated desmoplastic reaction in PDAC, we used AT1 knockout ( Agtr1a −/− ) mice and the FDA-approved AT1 blocker (ARB) losartan, which as we previously demonstrated reduces PSC activation, desmoplasia, and solid stress in PDAC ( 18 ) . In addition, we examined whether the obesity-exacerbated desmoplasia in PDAC results from increased infl ammation and immune cell infi ltration, and we uncovered the cellular and molecular mechanisms involved.
RESULTS

Diet-Induced or Genetically Induced Obesity Promotes Pancreatic Tumor Progression
We fed a high-fat diet (HFD) to four different strains of mice to generate diet-induced obesity (DIO; Fig. 1A ).
In addition, we used a genetic model of leptin defi ciency ( ob/ob ; Fig. 1A ) . Consistent with previous studies including those from our laboratory ( 27, 30, 31 ) , obesity promoted tumor initiation and progression across various tumor models. Using spontaneous PDAC models-KPC ( Ptf1-Cre/Kras LSL-G12D/+ /Trp53 LSL-R172H/+ ) and iKRAS ( Ptf1-Cre/ ROSA26-LSL-rtTa-IRES-eGFP/TetO-Kras TetO-LSL-G12D /Trp53 L/+ ) mice (32) (33) (34) (35) -we found that obese animals tended to develop tumors earlier than lean mice ( Supplementary Fig. S1 ). Furthermore, DIO and genetically induced obesity accelerated the growth of implanted tumors in two orthotopic syngeneic PDAC models-PAN02 and AK4.4. Similar to our previous observations ( 30 ) , in comparison with lean mice, obese mice presented with increased tumor weight ( Fig. 1B ) , increased metastatic dissemination to the mesenteric peritoneum in the PAN02 model ( Fig. 1Ci and ii ), and increased Figure 1. Obesity promotes tumor initiation and progression. A, generation of obese mouse models. High-fat (60%) versus low-fat (10%) diets started at 6 weeks of age generated a difference in body weight in multiple models. Data represent the body weight of WT C57BL/6 and FVB mice after 10 weeks on diet, and of the spontaneous PDAC models (KPC and iKRAS) at the time of tumor collection (between 15 and 20 weeks of diet for KPC, 12 to 16 weeks for iKRAS). Body weight of mice genetically defi cient for leptin ( ob/ob ) or age-matched WT mice was recorded after 7 weeks on a standard chow ( n = 8-10/group for C57BL/6, FVB, and ob/ob ; 4-10/group for KPC; 7-21/group for iKRAS). B, effect of obesity on tumor growth. Data in this panel represent the weight of tumors collected 3 weeks after implantation. PAN02 and AK4.4 syngeneic tumors were orthotopically implanted in C57BL/6 and FVB mice, respectively, at 10 weeks of diet (diets were continued until tumor collection); ob/ob mice and corresponding age-matched WT mice were implanted with PAN02 tumors at 7 weeks of age (mice under standard chow). Obese animals presented with higher tumor weights than lean counterparts in all models ( n = 8-10/group). C, effect of obesity on metastasis. Ci, representative images of mesenteric peritoneal dissemination observed in lean and obese mice 3 weeks after implantation of PAN02 tumors. White arrows, metastatic nodules in the mesentery. Cii, quantifi cation of mesenteric peritoneal metastasis in the PAN02 model ( n = 26-30/group). Ciii, quantifi cation of retroperitoneal metastasis in the PAN02 model and AK4.4 model ( n = 4-7/group). Data are shown as mean ± SEM. P values were determined by the Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001 . *** ii iii
The dysfunctional hypertrophic adipocytes that accumulate in visceral adipose and pancreatic tissues in obesity lead to the development of a local desmoplastic reaction characterized by fi brosis and infl ammation (20) (21) (22) . In tumors, desmoplasia promotes tumor growth and impairs response to chemotherapy via reduced vessel perfusion ( 18 ) . We hypothesized that obesity augments desmoplasia in the pancreatic tumor microenvironment, thus stimulating tumor progression. As expected ( 24 ) , in obese mice we observed hypertrophic adipocytes and associated fi brosis in the visceral adipose tissue ( Fig. 2Ai ). Importantly, we found that the tumor microenvironment also contained more and larger adipocytes ( Fig. 2Ai and iii ). In part, this was due to tumors invading the neighboring visceral WAT ( Supplementary Fig. S2A and S2B), as reported in patients with pancreatic cancer ( 7, 29 ) . Furthermore, Masson's trichrome staining revealed an abundant fi brosis in tumor areas enriched in adipocytes or alongside adjacent visceral adipose tissues ( Fig. 2Ai and iv ; Supplementary Figs. S2C and S3A). These data suggest that, in obesity, PDACs adopt a fi brotic adipose microenvironment as they invade the adjacent fi brotic adipose tissues. We next determined whether the abundance of fi brotic adipocyte-rich areas in tumors from obese mice led to an overall increase in tumor fi brosis. Using second harmonic generation (SHG) imaging, we found that obesity signifi cantly increased the SHG signal, which represents fi brillar collagen, in orthotopically grown PAN02 and AK4 tumors ( Fig. 2Bi and iii ). Obesity also signifi cantly increased collagen-I expression (immunofl uorescence) in the lesions of orthotopic and spontaneous PDACs ( Fig. 2Bii and iv ). Of note, within each body-weight setting, collagen-I levels did not correlate with tumor area, indicating that tumor size alone (increased in obesity) is not responsible for the observed increase in fi brosis in obese mice ( Supplementary Fig. S3B ). The tumor levels of hyaluronan (HA)-an ECM molecule also associated with desmoplasia-also tended to be higher in obese mice (Supplementary Fig. S3C and S3D). We then determined whether the presence of activated PSCs was also increased in tumors in obese mice. In obese animals, immunofl uorescence staining revealed a signifi cant increase in the density of alpha-smooth muscle actin (αSMA)-positive PSCs in PAN02 ( Fig. 2Ci and ii ). The numbers of αSMA-positive PSCs in AK4.4 and KPC models also tended to be higher in obese mice, and immunoblotting confi rmed signifi cant increases of αSMA in PAN02 and AK4.4 tumors ( Fig. 2Ci and ii ; Supplementary Fig. S3E ; see also Fig. 4C ). We confi rmed that αSMA-expressing PSCs associate with collagen-I expression in our PDAC models (Supplementary Fig. S3F and S3G ). Importantly, the percentage of PSCs associated with collagen-I expression increased by 2-to 3-fold in the obese setting ( Fig. 2Ciii ). Consistent with the increase in the fi brotic reaction in adipocyte-rich regions in tumors, the expression of αSMA also increased in these regions ( Fig.  6Bi and ii ). Taken together, we found that tumors in the obese setting are enriched in enlarged adipocytes, activated PSCs, and collagen-I.
Obesity-Aggravated Desmoplasia Is Associated with Impaired Vascular Perfusion, Intratumoral Drug Delivery, and Treatment Effi cacy
We have reported that desmoplasia reduces the delivery and effi cacy of chemotherapy in PDAC by decreasing vessel perfusion ( 18 ) . Therefore, we tested if obesity-augmented desmoplasia reduced the effi cacy of chemotherapy. Indeed, we found that in obese animals, the tumor vascular perfu-sion was reduced ( Fig. 3Ai -iii ). In both PAN02 and AK4.4 tumors, the percentage of perfused vessels per total tumor area signifi cantly decreased from 2.5% to 0.75% (from ∼25% to 10% of total vessel area). Consistent with this fi nding, we observed an increase in hypoxia markers in tumors from obese mice ( Fig. 3B ; Supplementary Fig. S4 ). To determine if reduced perfusion impairs the delivery of chemotherapeutic agents, we measured the uptake of 5-Fluorouracil (5-FU), an approved cytotoxic agent used in the treatment of PDAC ( 36 ) . Obesity signifi cantly decreased the uptake of 5-FU in PAN02 tumors ( Fig. 3C ) and reduced the effi cacy of 5-FU chemotherapy in both PAN02 and AK4.4 tumors ( Fig. 3D ). The 5-FU treatment signifi cantly reduced the tumor weight in lean mice ( Fig. 3D ). In contrast, in obese mice, 5-FU did not signifi cantly affect the growth of PAN02 and AK4.4 tumors ( Fig. 3D ). Collectively, these data show that, in addition to directly promoting PDAC growth and metastasis, obesity reduces vascular perfusion, drug delivery, and the effi cacy of 5-FU chemotherapy. Supplementary Fig. S4 ). Obese mice presented with increased hypoxia in tumors. C, effect of DIO on the delivery of chemotherapy to PAN02 tumors. 5-FU quantifi ed via highperformance liquid chromatography (HPLC). Obesity decreased delivery of the chemotherapeutic agent ( n = 4 tumors/group). D, Effect of DIO on response to chemotherapy. PAN02 and AK4.4 tumors were orthotopically implanted at 10 weeks of diet, treatments were initiated at day seven after implantation, and tumors were resected at day 19 (after three cycles of 5-FU 30 mg/kg q4d). 5-FU was less effective in preventing tumor growth in obese animals than in lean (two-way ANOVA, n = 6-10/group). Data are shown as mean ± SEM. P values were determined by the Student t test unless otherwise stated. *, P < 0.05; **, P < 0.01.
Tumor weight (grams)
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RESEARCH ARTICLE The Inhibition of AT1 Signaling Reduces Obesity-Induced Desmoplasia and Tumor Growth and Increases the Response to Chemotherapy
We have shown that tumor desmoplasia results in part from the activation of PSCs through AT1 signaling ( 18 ) . We confi rmed the expression of AT1 in PSCs (AT1/αSMA double staining), which ranged from 70.3% (SEM = 5.7) in PSCs in PAN02 tumors to 35.3% (SEM = 12.8) in AK4.4 tumors (Supplementary Fig. S5A ). We next analyzed the effects of obesity on AT1 downstream pathways. In both PAN02 and AK4.4 tumors, obesity increased the activation of p38, ERK, AKT, and their targets pS6 and 4EBP1 ( Fig. 4A ; refs. 18, 37-39 ). In addition, several target genes of the AT1 pathway, including Col1a2, Tgfβ1, and matrix metalloproteinases genes, were upregulated ( Fig. 4Bi and ii ; Supplementary Tables S1-S2).
To test if the inhibition of AT1 signaling could reverse desmoplasia in obese mice, we used the ARB losartan and mice defi cient in AT1 ( Agtr1a −/− ). In AK4.4 tumors in obese but not lean mice, the 16-day losartan treatment significantly reduced the gene and protein expression of the PSCactivation marker αSMA ( Fig. 4Ci and ii ; Supplementary  Fig. S5B ). Similarly, in obese mice, losartan signifi cantly decreased the SHG signal for fi brillar collagen and reduced collagen-I immunofl uorescence, though not signifi cantly ( Fig. 4Di -iv ). Moreover, in AK4.4, losartan normalized the obesity-induced expression of desmoplasia-related markers (αSMA, decorin, SMAD2, p-p38) and ECM remodeling (MMP9; Fig. 4Ei and ii ; and Supplementary Fig. S5B ). These effects were absent or only modest in lean animals, consistent with the small reduction in αSMA expression in this weight setting. Similarly, in obese mice with PAN02 tumors, losartan signifi cantly reduced the collagen-I content ( Fig.  4Dv ) , and losartan or AT1 deletion reduced the expression of αSMA ( Supplementary Fig. S3Ei and S3Eii; Supplementary Fig. S5C ). Furthermore, intimately associated with AT1 signaling, the epithelial-to-mesenchymal (EMT ) markers MMP9, SNAIL, and vimentin were increased in AK4.4 tumors from obese mice in both models and were subsequently normalized by losartan ( Fig. 4E ; Supplementary Fig. S5B ). In PAN02 tumors, we confi rmed that AT1 deletion normal-ized the obesity-increased expression of vimentin (Supplementary Fig. S3Ei and S3Eiii).
We then determined whether AT1 blockade could improve the response to chemotherapy, particularly in obese mice with desmoplastic tumors. In a previous study, we found that losartan combined with 5-FU signifi cantly inhibited the growth of AK4.4 tumors in mice fed a regular diet, but losartan alone had no effect on tumor growth ( 18 ) . Consistent with this, in the current study in lean mice, the genetic deletion of AT1 or the losartan treatment had no effect on tumor size in PAN02 and AK4.4 models. However, in obese mice with a genetic deletion of AT1 or treated with losartan, the tumor sizes were signifi cantly smaller ( Fig. 4Fi and ii ). Similar to the data of Fig. 3D , 5-FU alone signifi cantly reduced the size of AK4.4 and PAN02 tumors in lean but not in obese mice. The combination of genetic AT1 blockade plus 5-FU signifi cantly reduced tumor size compared with either treatment alone in obese but not in lean animals ( Fig.  4Fi ). Similarly, in both AK4.4 and PAN02 tumors, losartan signifi cantly enhanced the response to 5-FU in obese but not in lean animals, although it was still somewhat effective in the lean setting in the AK4.4 model ( Fig. 4Fi and ii ). However, because losartan alone was effective in decreasing tumor growth in obese mice ( Fig. 4Fi and ii ; Supplementary  Fig. S5D ), the tumor size in losartan-versus losartan plus 5-FU-treated groups in obese mice did not signifi cantly differ ( Fig. 4Fi and ii ). Importantly, we confi rmed via abdominal ultrasound that, when treatment was initiated, tumors had similar size in all groups (lean and obese, control vs. losartan; Supplementary Fig. S5D ). In addition to AT1, we recently observed that PSCs also express the angiotensin II type-2 receptor (AT2), which has antifi brotic effects as opposed to the profi brotic effects of AT1 signaling ( 18 ) . However, we found here that the PAN02 tumor response to chemotherapy in AT2 -/mice was similar to that in wild-type (WT) mice, regardless of diet group ( Fig. 4Fi ).
Similar to our previous study ( 18 ) , we analyzed whether the increase in 5-FU antitumor effi cacy induced by losartan in obese animals could be at least in part due to improvements in vascular perfusion and drug delivery. In both AK4.4 and PAN02 models, we found a trend for increased tumor Pixel count 
RESEARCH ARTICLE
perfusion and increased delivery of chemotherapeutics by AT1 blockade ( Supplementary Fig. S5E and S5F ). The mild effects on tumor perfusion could be the consequence of a reduced mean arterial blood pressure (MABP) induced by the relatively high dose of losartan (90 mg/kg/day). In fact, losartan reduced the MABP by approximately 27% in both lean and obese mice ( Supplementary Fig. S5G ). Of note, AT1 blockade did not induce greater loss in body weight in tumorbearing mice compared with WT, suggesting that based on this parameter, it does not appear to cause overall toxicity ( Supplementary Fig. S5H ).
In conclusion, we found that obesity is associated with increased AT1 signaling in tumors; that in obese animals, losartan alone or the genetic blockade of AT1 has direct antitumor effects; and that AT1 inhibition can also enhance the effi cacy of 5-FU chemotherapy.
Tumor-Associated Neutrophils Mediate Obesity-Induced PSC Activation and Tumor Progression
The fi brotic phenotype in adipose tissues and normal pancreas in obesity is largely the consequence of a persistent proinfl ammatory state, which is characterized by the production of cytokines by hypoxic and dysfunctional hypertrophic adipocytes and the recruitment of immune cells ( 21, 22, 34 ) . In addition, we have previously described increased infl ammation and immune cell recruitment in PAN02 tumors implanted in obese mice ( 30 ) . Hence, we next determined here whether adipocyte-associated infl ammation was responsible for the increased tumor desmoplasia and accelerated tumor growth observed in obese animals. Flow cytometric analysis revealed that obesity promotes the infi ltration of CD11b + Gr1 + F4/80myeloid cells in orthotopic AK4.4 and PAN02 PDAC models in obese mice ( Fig. 5A ; Supplementary  Fig. S6A ). We subsequently confi rmed that the majority of infi ltrated myeloid cells were Ly6G + tumor-associated neutrophils (TAN; Supplementary Fig. S6B ). In both PAN02 and AK4.4 tumors, TAN depletion (TAN-D)-with an anti-Ly6G antibody that decreased TAN infi ltration by 90% (Supplementary Fig. S7A )-reverted the increased tumor growth in obese mice to levels in lean mice ( Fig. 5Bi and ii ). This effect occurred only when TAN-D was initiated on day 1 but not on day 7 of the experiment, indicating the relative importance of TANs in tumor progression at an early stage ( Fig. 5Bi ) . In addition to a direct effect on tumor growth, we determined whether TANs could affect desmoplasia. We observed the preferential accumulation of TANs in areas with activated PSCs ( Fig. 5C ), suggesting a potential paracrine cross-talk between TANs and PSCs. Indeed, TAN-D in PAN02 tumors in obese animals decreased PSCs and the number of activated PSCs associated with collagen-I to levels in lean animals ( Fig.  5Di and ii, and E ). Consistent with this, we observed a significant reduction in AT1 expression and a trend for decreased collagen-I and MMP9 expression in PAN02 tumors ( Fig. 5E ). In addition, TAN-D signifi cantly increased the vascular surface area and the number of perfused vessels in PAN02 tumors, but not signifi cantly in AK4.4 tumors ( Fig. 5F ; Supplementary Fig. S7Bi and S7Bii). Our data suggest that obesity increases TAN recruitment in PDAC, which mediates the activation of PSCs and tumor growth.
IL1a Mediates Obesity-Induced TAN Infi ltration and PSC Activation in PDACs
The obesity-induced proinfl ammatory/profi brotic response and immune cell recruitment that occur in adipose tissue are mediated by cytokine/chemokine production from dysfunctional adipocytes, such as IL1β and IL6 ( 21, 22, 40 ) . Hence, we determined whether these infl ammatory cytokines mediated obesity-induced fi brotic processes and TAN infi ltration in the tumor microenvironment. We confi rmed our previous observation ( 30 ) that in PAN02, obesity signifi cantly increased the expression of IL1β by 5-fold and induced a trend toward increased expression of IL6, TNFα, IL12, or CXCL1 ( Fig. 6A ) . Obesity also increased the levels of IL1β in AK4.4 tumors ( Supplementary Fig. S8 ). Not surprisingly, IL1β was abundantly expressed by adipocytes in adipocyte-rich areas where activated PSCs predominate ( Fig. 6Bi , top row fi gure, and ii). Antibody neutralization of IL1β (MM425B; Endogen/Pierce Biotechnology; 2 mg/Kg i.p. q4d)-in obese mice implanted with PAN02 tumors-signifi cantly decreased TAN infi ltration. In addition, the decreased TAN recruitment was associated with an increase in CD8 + cytotoxic T-cell population (decreased in obese mice compared with lean) and a decrease in regulatory T cells (Treg; Fig. 6Ci and ii ). Similar to TAN-D effects, IL1β inhibition in obese animals signifi cantly reduced the growth of PAN02 tumors ( Fig. 6D ) as well as the expression levels of αSMA ( Supplementary Fig. S3E ). In addition, the EMT marker vimentin was also reduced by IL1β inhibition in obese mice ( Supplementary Fig. S3E ). In addition to adipocytes, IL1β was also expressed in about 70% of TANs themselves ( Fig. 6E ) , and TAN-D reduced tumor IL1β levels ( Fig. 6F ). This suggests the presence of an autocrine mechanism that enables further TAN recruitment and potentiates infl ammation and fi brosis. Furthermore, TAN-D signifi cantly reduced the levels of CXCL1, indicating that this cytokine may also play a role in obesity-induced infl ammation (Supplementary Fig. S9 ). In conclusion, our fi ndings suggest IL1β is involved in obesity-induced TAN recruitment, immunosuppressive microenvironment, and PDAC progression.
AT1 Blockade Can Reciprocally Inhibit Infl ammation and Immune Cell Infi ltration in Obesity
We observed that αSMA-positive PSCs also abundantly (∼70% of PSCs) expressed IL1β ( Fig. 6Bii and G ) and that of the total cells expressing IL1β, PSCs correspond to 40% of these cells in adipocyte-poor but 70% in adipocyte-rich (∼70% increase) regions ( Fig. 6Bi and ii ) . Because IL1β recruits TANs, which localize in close proximity to PSCs as shown above, we next examined whether targeting PSCs could also interfere with IL1β production and TAN recruitment, particularly in obese mice. Indeed, in obese mice, prevention of PSC activation by losartan inhibition of AT1 signaling decreased IL1β levels in AK4.4 and PAN02 tumors ( Supplementary Fig. S10A ). In addition, the genetic deletion of AT1 decreased TAN recruitment in PAN02 tumors in obese but not lean mice ( Fig. 6Ci and ii ) . Consequently, recapitulating IL1β inhibition, AT1 blockade increased CD8 + T cells and reduced Tregs in tumors from obese but not lean mice ( Fig. 6Fi- 
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for losartan in the AK4.4 tumor model ( Supplementary  Fig. S10Bi and S10Bii). The effects of AT1 blockade on the expression of IL1β and immune cell recruitment are consistent with the prevention of obesity-induced tumor growth ( Fig. 4F ) and indicate that AT1 signaling mediates obesity-augmented tumor progression via modulation of the immune microenvironment.
PDAC in Obese Patients Presents with Increased Adipocyte Area and Fibrosis
To validate the fi ndings from mouse models of PDAC, we obtained samples of PDAC from treatment-naïve patients who presented with a body mass index (BMI) either below 25 (normal weight) or above 30 (obese). As in the mouse models, we found that tumors from obese patients presented with hypertrophic adipocytes ( Fig. 7A ) and more pronounced ECM deposition-as shown by increased collagen-I and HA expression ( Fig. 7B ).
Excess Weight in Patients with PDAC Is Associated with Worse Response to Chemotherapy
To validate our preclinical fi ndings, we analyzed data collected from patients admitted to Massachusetts General Hospital (MGH) with a diagnosis of PDAC who underwent surgical resection. A total of 309 patients were included in this study. The average BMI of patients was 26.25 (BMI distribution in Supplementary Fig. S11 ). In normal-weight patients (BMI ≤ 25), adjuvant chemotherapy was a signifi cant Obesity promoted infi ltration of myeloid CD11b + Gr1 + F4/80cell population in PAN02 tumors in obese mice. Quantifi cation normalized by total viable cells (i) or total CD45 leukocytes (ii; n = 4-6 tumors/group). B, effect of TAN-D on PDAC growth in obese mice. TAN-D from day 1 using anti-Ly6G-specifi c pharmacologic inhibitory antibody in obese mice signifi cantly reverted the obesity-increased tumor weight in PAN02 and AK4.4 models ( n = 4-6 tumors/ group). C, preferential accumulation of TANs in areas with activated PSCs. Scale bars, 1 mm (whole tumors) and 100 μm (inset). D, TAN-D decreased activated PSCs in obese PDACs to the level of lean tumors. Representative pictures (i) and quantifi cation of αSMA + Col-I + double-positive cells (ii; n = 4-6 tumors/group). E, TAN-D reduced AT1 expression, collagen production, and MMP9 expression in PAN02 tumors in obese animals. Representative Western blots (i) and quantifi cation (ii) are shown. F, TAN-D led to increasing in perfusion in PAN02 tumors in obese animals. Percentage of CD31 + , lectin + , or double-positive vessel density in the viable area of whole tumors ( n = 4-6 tumors/group). Data are shown as mean ± SEM. P values were determined by the Student t test, or one-way ANOVA for C and E. *, P < 0.05; **, P < 0.01; *** P < 0.001. The survival advantage present in the BMI ≤ 25 subgroup is lost in the >25 BMI subgroup. D, graphical summary of the key fi ndings of this study. PDACs in obese hosts present with increased fatty stroma, infl ammation, and desmoplasia. The amplifi ed cross-talk between CAAs, TANs, and PSCs that occurs in obesity leads to an aggravation of desmoplasia, increased tumor progression, and reduced response to chemotherapy. 
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predictor of overall survival on multivariate analysis (HR, 0.5; 95% confi dence interval, 0.3-0.8; P < 0.005), independent of other tumor characteristics including tumor size or lymph node positivity ( Fig. 7Ci ; Supplementary Tables S3  and S4 ). In overweight and obese patients (BMI > 25), we did not observe a signifi cant survival advantage of adjuvant chemotherapy on either univariate or multivariate analysis ( Fig. 7Cii ; Supplementary Tables S5-S6 ). In conclusion, these results support our preclinical fi ndings and suggest less effi cacy of chemotherapy in overweight/obese patients. In conclusion, our preclinical and clinical studies indicate that excess weight alters the tumor microenvironment to augment the cross-talk between CAAs, TANs, and PSCs, which ultimately leads to increased tumor progression and reduced response to chemotherapy ( Fig. 7D ).
DISCUSSION
Obesity Promotes AT1-Dependent PSC Activation and PDAC Desmoplasia and Reduces the Effi cacy of 5-FU Chemotherapy
We and others have shown that obesity promotes pancreatic tumor initiation, growth, and metastasis in preclinical models ( 27, 30, (41) (42) (43) (44) . Here, we show in established PDAC models that obesity stimulates the activity of IL1β and the cross-talk between adipocytes, TANs, and PSCs to worsen the fi broinfl ammatory microenvironment. The increased fi broinfl ammatory activity then promotes tumor progression and reduces vascular perfusion, drug delivery, and the effi cacy of chemotherapy. We also uncovered that AT1 signaling can mediate obesity-induced PSC activation and increase collagen-I accumulation. The inhibition of AT1 signaling is particularly effective in preventing these effects in obese animals, reverting the obesity-accelerated tumor progression and resensitizing tumors to the chemotherapeutic agent 5-FU in obese mice.
In Obese Mice, the Abundance of Adipocytes and TANs Increases PSC Activation via IL1a Particularly in Adipocyte-Rich Regions
In more than half of patients with PDAC, adipocytes infi ltrate >20% of pancreatic tissue ( 28 ) . Similar to previous reports ( 27, 28, 45 ) , we demonstrated that hypertrophic tumor adipocytes-referred to as cancer-associated adipocytes (CAA; refs. 45, 46 )-accumulate in murine and human PDAC in the obese setting. It is well known that obesity promotes the secretion of infl ammatory cytokines from hypertrophic adipocytes in adipose tissues and the pancreas, which ultimately leads to local tissue fi brosis ( 21, 22, 25, 47 , 48 ) . However, how hypertrophic CAAs facilitate the interaction between infl ammation and desmoplasia to ultimately promote PDAC progression in the obese setting was unknown. We observed here an accumulation of activated PSCs and fi brosis surrounding CAA-rich areas. Given the increased adipocyte burden, the overall PSC activation and fi brotic content in tumors were consequently increased. We also found in obese mice that CAAs express IL1β, which increases the production of IL1β in PDAC, especially in CAA-rich areas. In line with IL1β being an activator of PSCs ( 49 ), we found that IL1β inhibition reduces PSC activation in PDACs in obese animals, indicating that the elevated production of IL1β in CAA-rich regions leads to activation of PSCs. This is in agreement with previous reports showing that in the pancreas of mice fed a high-fat diet, fi brosis is also accompanied by infl ammation in early-stage neoplastic lesions ( 43, 44 ) , and with our previous observation that metformin reduces IL1β and desmoplasia in tumors implanted in obese mice ( 50 ) . It was shown before that neutrophil infi ltrates can be observed in the vicinity of tumor cells and in the desmoplastic tumor stroma, which correlates with undifferentiated tumor growth and poor prognosis ( 51 ) . We found that TANspecifi c depletion reduces PSC activation and the number of αSMA-positive cells associated with collagen-I. In addition, we discovered that IL1β could recruit/activate TANs. This is consistent with previous reports of increased levels of myeloperoxidase-a marker of intrapancreatic neutrophil sequestration/activation-associating with IL1β in the steatotic pancreas of obese mice ( 25, 52 ) . Furthermore, our results show that TANs also secrete IL1β, which may then activate PSCs and further increase TAN recruitment. Our results explain the fi ndings that, in patients with pancreatic cancer, the intrapancreatic fat correlates with the increased incidence of PDAC and lymphatic metastasis, and decreased survival ( 28, 53 ) . In conclusion, in obese mice, the cross-talk between adipocytes, TANs, and PSCs-mediated in part by IL1β-stimulates the activation of PSCs.
Obesity-Induced TAN Recruitment and IL1a Promote Immunosuppression and the Growth of PDAC
We also found here that TAN-D in obese mice reduced tumor growth, which is consistent with the correlation between TAN infi ltration and more aggressive types of pancreatic tumors ( 54 ) . Importantly, the obesity-induced increase in TANs occurred concomitantly with decreased CD8 + T cells and increased Tregs, which is typical of an immunosuppressive microenvironment that promotes tumor progression ( 55, 56 ) . In fact, we previously found that obesity is associated with an increased expression of the immunosuppressive molecules IL4 and IL5 in PAN02 tumors ( 30 ) , which was confi rmed here in the AK4.4 model ( Supplementary Fig.  S8B ). Furthermore, we found here that IL1β inhibition recapitulates the effect of TAN-D on the immune phenotype and tumor growth, consistent with the TAN-recruiting effect of IL1β. These fi ndings extend our previous observations that obesity is associated with infl ammation, immunosuppression, and macrophage recruitment in PAN02 tumors, and that reducing IL1β production via VEGFR1 inhibition leads to a reduction in tumor progression in obese mice ( 30 ) . Considering that the immune environment in obesity appears to be suppressed, and the unprecedented success of therapies that block immune checkpoint pathways ( 55 ) , it would be interesting to evaluate whether these therapies will be particularly effective in obese hosts.
Obesity Promotes the Cross-talk between CAAs, TANs, and PSCs That Leads to PDAC Growth
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infi ltration of TANs and Tregs, increases the number of CD8 + T cells, and reduces obesity-associated tumor growth. These fi ndings suggest that the interaction of infl ammatory cells and PSCs is bidirectional-targeting TANs reduces PSC activation, and, in turn, targeting PSCs reduces the recruitment of TANs, with both approaches reducing tumor growth. This is consistent with previous in vitro work demonstrating that neutrophils interact reciprocally with myofi broblasts and PSCs ( 57, 58 ) . In conclusion, our work reveals a cross-talk between CAAs, TANs, and PSCs that promotes tumor progression in obese hosts, with IL1β (secreted by all these cells) playing a major role in this cooperation ( Fig. 7D ).
AT1 Inhibition Reverses Obesity-Induced PDAC Growth
Similar to our previous results in mice fed a regular diet ( 18 ) , losartan or AT1 deletion did not affect the growth of PDAC in lean mice. In contrast, in obese animals AT1 inhibition reduced PDAC growth, which was likely due to the inhibition of the protumorigenic activity of TANs and IL1β, which modulate the recruitment/activity of CD8-positive T cells and Tregs, as discussed above. The reduction of TAN recruitment after AT1 inhibition may result from a direct effect, because neutrophils have been shown to express AT1 ( 59, 60 ) . Indeed, we found that approximately 40% of TANs expressed AT1 in the PAN02 model ( Supplementary Fig. S12 ) and similarly in AK4.4 and KPC models (data not shown). Alternatively, the effects of AT1 blockade on immune cell recruitment could also be indirect. We showed that IL1β recruits TANs, and AT1 inhibition reduced the production of IL1β. This could be due to AT1 inhibition of PSCs or tumor adipocytes, as both cells express AT1 and produce IL1β. In fact, AT1 is highly expressed in normal adipocytes ( 23 ), its activity is increased in adipose tissues in obesity ( 23, 24 ) , and we show here that it is expressed in CAA as well (Supplementary Fig. S13 ). Moreover, AT1 deletion reduced the levels of the TAN chemoattractant CXCL1 and the TAN activation molecule INFγ in tumors ( Supplementary Fig. S14A ), which can also explain the reduced TAN infi ltration.
On the other hand, AT1 inhibition in obese mice reduced the expression of hypoxia and EMT markers in tumors (Supplementary Figs. S3E and S14B), likely due to its effects on the desmoplastic microenvironment ( Supplementary Fig. S3E ). These effects of AT inhibition may have also contributed to the reduction of tumor progression in obesity. In addition, obesity also increased AKT/ERK, p38, JNK, and pS6/4EBP1 signaling, which is involved not only in AT1 signaling/desmoplasia in PSCs, but also in proliferation and survival of PDAC cells (61) (62) (63) . Because losartan reduced the activation of some of these signaling pathways (p38/JNK/4EBP1), its effects on tumor growth may also be explained by a direct effect on cell proliferation/survival.
AT1 Ablation Reverses Obesity-Induced Chemoresistance
In contrast to the antitumor effects of losartan, 5-FU reduced PDAC growth in lean but not obese mice, which could be due to the signifi cantly lower intratumoral vascular perfusion and 5-FU uptake in obese than lean mice. In obese mice, AT1 deletion signifi cantly increased the antitumor activity of 5-FU, whereas the effect of the combination of losartan and 5-FU was not superior to 5-FU alone. In fact, and in contrast to our previous study ( 18 ) , the increased 5-FU activity induced by losartan was not related to a signifi cant increase in vascular perfusion or drug uptake. Blood fl ow in tumors is known to be highly dependent on the MABP ( 64 ); thus, it is possible that the signifi cant decrease in MABP induced by the relatively high dose of losartan (90 mg/kg) may have affected the tumor blood fl ow, thus minimizing the positive effects of losartan on vascular perfusion. Apart from the effects of losartan on TANs or the adaptive immune response, the losartan-induced decrease in SNAIL expression and phospho-p38 may also increase the cytotoxic activity of 5-FU. p38 is known to be involved in chemoresistance ( 65 ) , and in mouse models of pancreatic cancer, SNAIL deletion increased the antitumor activity of gemcitabine ( 66 ) .
Of note, consistent with previous work in PAN02 tumors ( 67 ), by using both genetic and diet-induced obese mouse models we determined that obesity promotes tumor growth independent of diet. This was also confi rmed by the fi nding that FVB mice that did not gain weight despite an HFD (∼25% of all mice on an HFD) were observed to have tumor growth similar to that in lean animals (not shown).
Validation of Preclinical Findings in Patients with PDAC
We found that our key observations in mice were also present in patients. In particular, excess weight was associated with increased number and size of adipocytes and desmoplasia in tumors and reduced response to chemotherapy. Although the specifi c effect of obesity on patients with PDAC in a neoadjuvant setting is not known, we found that obesity adversely affected patients with PDAC who received adjuvant chemotherapy. Moreover, the high incidence (∼85% in our cohort; Supplementary Fig. S15 ) of hypertension in obese patients makes it an ideal target population for AT1 inhibitors (ACERi/ARBs), considering the blood pressure-lowering effect of these drugs.
CONCLUSIONS
Obesity is considered to be responsible for 14% to 20% of all cancer-related deaths in the United States ( 4 ). As a result, the obesity epidemic-which also affects the majority of patients with PDAC-highlights the importance of understanding the pathophysiology underlying the obesity-cancer connection. We had previously found that obesity associates with increased tumor infl ammation, immune cell recruitment, and tumor growth. We discovered here that obesity-induced infl ammation and TAN infi ltration lead to a desmoplastic tumor microenvironment, which directly promotes tumor growth and impairs the response to chemotherapy. Both of these factors may explain the poor outcomes in obese patients. The fi nding that obesity-induced desmoplasia responds to clinically available antifi brotic therapies (e.g., ARBs) is extremely encouraging and strongly supports the implementation of clinical trials to determine the effi cacy of these therapies in obese patients with PDAC in combination with the current standard of care. Because epidemiologic and molecular evidence suggests a link between obesity and other desmoplastic cancer types, the strategies established in this study may also apply to on August 20, 2017. © 2016 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from RESEARCH ARTICLE a broader patient population. In conclusion, obesity and the obesity-related markers described here (increased desmoplasia, TAN infi ltration, and IL1β expression) may help explain the poorer prognosis in patients with PDAC.
METHODS
Obese Mouse Models
C57BL/6 WT, leptin-defi cient ( ob/ob ), AT1-knockout (KO; agtr1a −/− ) or AT2-KO ( agtr2 −/− ; all C57BL/6 background), and FVB mice were originally obtained from The Jackson Laboratory and bred and maintained in our defi ned fl ora animal colony. KPC (PTF1-Cre/LSL-KRAS G12D /p53-R172H, mixed C57BL/6 and FVB background) and iKRAS (p48-Cre;R26-rtTa-IRES-EGFP;TetO-Kras G12D mice, FVB background; refs. 32-35, 68 ) mice were obtained from our collaborators. To generate an obese model, mice (6 weeks old) were given either a 10% or a 60% fat diet (D12450J and D12492; Research Diets) for 10 weeks (or until tumor collection in KPC spontaneous models), as previously described (68) (69) (70) Supplementary Methods) . With exception of PAN02, these orthotopically grown pancreatic cancers are characterized by a dense collagenous stroma, a hallmark of pancreatic cancer desmoplasia ( 73 ) . All experimental uses of animals abide by the Public Health Service Policy on Humane Care of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at Massachusetts General Hospital.
Pancreatic Tumor Growth Studies
For all experiments unless specifi ed below, mice bearing orthotropic PAN02 or AK4.4 pancreatic tumors were randomized into treatment groups (or controls), and tumors were collected at day 21 after implantation. For the tumor growth study with chemotherapy, mice were divided into treatment groups 7 days after implantation when tumors in lean and obese mice had similar sizes, as determined by ultrasound ( Supplementary Fig. S5J ), and treated with either 5-FU (30 mg/kg i.v. every 4 days) or an equal volume of saline by intravenous injection on days 7, 11, and 15 after implantation, with tumors collected at day 19. For the tumor growth study with losartan, mice were treated with losartan (90 mg/kg i.p. every day) or an equal volume of PBS intraperitoneally starting on day 5 after implantation for the duration of the study. In the combined experiment of losartan and 5-FU, the same protocol was used for each drug as described above. TAN-D by a Ly6G-specifi c inhibitor (BioExcell; 4 mg/Kg i.p. every 2 days) was administered starting at day 1 or day 7. IL1β inhibition (MM425B; Endogen/Pierce Biotechnology; 2 mg/kg i.p. every 2 days) was administered to PAN02-bearing animals starting at day 7. At the completion of the study, adipose tissue and tumor samples were collected, weighed, and processed for further analysis (for information on rtPCRarray, immunohistochemistry/immunofl uorescence, Western blotting, ELISA, and fl ow cytometry, please see Supplementary Methods). When spontaneous models were used, tumors were collected when palpable. For drug delivery in tumors, drug preparation, and ultrasound and blood pressure measurements, please refer to Supplementary Methods.
Human Samples/Clinical Studies
Human samples of pancreatic cancer were obtained from the MGH tissue repository. Tumors selected received no prior chemotherapy or radiotherapy before the surgical specimen was collected at the time of tumor resection. BMI was obtained for the respective sample. A total of 16 samples were randomly selected from this subset of samples (8 with BMI < 25 and 8 with BMI > 30). Paraffi n sections were stained for collagen-I and HA as described below. Images were acquired using confocal microscopy and quantifi ed using Matlab. Data were analyzed anonymously. For survival studies, 309 consecutive patients with pancreatic cancer who received surgical resection who were followed up in MGH between 2006 and 2010 with information including clinicopathologic details, treatment received, and BMI at the time of diagnosis were included. Written informed consent from the patient or the next of kin was obtained for the use of pancreatic cancer samples or clinical data. All studies were conducted in accordance with the Declaration of Helsinki and were approved by an Institutional Review Board. All patients have a pathology-confi rmed diagnosis of PDAC.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism Version 6.0f (GraphPad Software) and SPSS software (for clinical studies), version 22 (SPSS). Error bars indicate the SEM of data from replicate experiments. The signifi cance of difference between samples within fi gures was confi rmed using unpaired t tests, oneway ANOVA, χ 2 test, or two-way ANOVA, depending on the experimental setting. In clinical studies, patients were divided into BMI ≤ 25 ( n = 145), or BMI > 25 ( n = 164), with mean BMI being 26.25 . The values of BMI represent the BMI at the time of diagnosis. Overall survival was defi ned as the time from date of diagnosis until date of death or last contact. Survival curves were calculated using Kaplan-Meier methods and were compared using the logrank test. Covariates with a P value < 0.150 in univariate analysis were included into multivariate analyses. Cox proportional hazards regression analyses were used to conduct comparisons for chemotherapy effi cacy. The association of adjuvant chemotherapy and overall survival was adjusted for tumor size (continuous variable), lymph vessel and perineural invasion (absent vs. present), lymph nodes (negative vs. positive), surgical margin (negative vs. positive), pathologic grading (1-2 vs. 3-4), adjuvant radiation (yes vs. no), and adjuvant chemotherapy (yes vs. no). Time to event was diagnosis of pancreatic cancer until death or last follow-up with individuals still alive at last follow-up being coded as censored for the event (death) as of that date. For comparison between prevalence of hypertension, a χ 2 test was performed. In all analyses, a P value of less than 0.05 was considered signifi cant. 
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